Endometriosis Patients Undergoing Quinagolide Treatment

Endometriosis Clinical Trial

Official title:

Effect of Treatment With Agonist Dopaminergics on Endometriosic Lesions.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00625950
• Other study ID #: VLC-AP-10208-208-1
• Status: Completed
• Phase: Phase 4
• First received: February 20, 2008
• Last updated: January 9, 2009
• Start date: February 2008
• Est. completion date: May 2008

Study information

• Verified date: January 2009
• Source: Instituto Valenciano de Infertilidad, IVI VALENCIA
• Contact: n/a
• Is FDA regulated: No
• Health authority: Spain: Ethics Committee
• Study type: Interventional

Clinical Trial Summary

Dopamine agonists, such as quinagolide, are able to act on the VEGFR-2 blocking antibodies, diminishing Vascular Endothelial Growth Factor effect on angiogenesis in human endometriotic lesions.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 5
• Est. completion date: May 2008
• Est. primary completion date: April 2008
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 37 Years

Eligibility

Inclusion Criteria:

• Hyperprolactinemia

• Unexplained infertility

• Endometriosis

Study Design

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research

Related Conditions & MeSH terms

• Endometriosis
• Hyperprolactinemia

Intervention

Procedure:
• ENDOMETRIAL BIOPSY
Two routine laparoscopies in period of three months with endometrial biopsy comparative study performed.

Locations

Country	Name	City	State
Spain	Instituto Valenciano de Infertilidad	Valencia

Sponsors (1)

Lead Sponsor	Collaborator
Instituto Valenciano de Infertilidad, IVI VALENCIA

Country where clinical trial is conducted

Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	observation of three month treatment with Quinagolida in endometriosis patients		onset and three months after onset	No